The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Abstract
Between August 1990 and August 1995, 231 patients (median age 51, 53% Durie-Salmon stage III, median serum β-2-microglobulin 3.1 g/L, median C-reactive protein 4 g/L) with symptomatic multiple myeloma were enrolled in a program that used a series of induction regimens and two cycles of high-dose therapy (“Total Therapy”). Remission induction utilized non–cross-resistant regimens (vincristine-doxorubicin-dexamethasone [VAD], high-dose cyclophosphamide and granulocyte-macrophage colony-stimulating factor with peripheral blood stem cell collection, and etoposide-dexamethasone-cytarabine-cisplatin). The first high-dose treatment comprised melphalan 200 mg/m2 and was repeated if complete (CR) or partial (PR) remission was maintained after the first transplant; in case of less than PR, total body irradiation or cyclophosphamide was added. Interferon--2b maintenance was used after the second autotransplant. Fourteen patients with HLA-compatible donors underwent an allograft as their second high-dose therapy cycle. Eighty-eight percent completed induction therapy whereas first and second transplants were performed in 84% and 71% (the majority within 8 and 15 months, respectively). Eight patients (3%) died of toxicity during induction, and 2 (1%) and 6 (4%) during the two transplants. True CR and at least a PR (PR plus CR) were obtained in 5% (34%) after VAD, 15% (65%) at the end of induction, and 26% (75%) after the first and 41% (83%) after the second transplants (intent-to-treat). Median overall (OS) and event-free (EFS) survival durations were 68 and 43 months, respectively. Actuarial 5-year OS and EFS rates were 58% and 42%, respectively. The median time to disease progression or relapse was 52 months. Among the 94 patients achieving CR, the median CR duration was 50 months. On multivariate analysis, superior EFS and OS were observed in the absence of unfavorable karyotypes (11q breakpoint abnormalities, -13 or 13-q) and with low β-2-microglobulin at diagnosis. CR duration was significantly longer with early onset of CR and favorable karyotypes. Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and β-2-microglobulin. Total Therapy represents a comprehensive treatment approach for newly diagnosed myeloma patients, using multi-regimen induction and tandem transplantation followed by interferon maintenance. As a result, the proportion of patients attaining CR increased progressively with continuing therapy. This observation is particularly important because CR is a sine qua non for long-term disease control and, eventually, cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Analysis of survival by tumor response.
Anderson, J. R., Cain, K. C., & Gelber, R. D. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.11.710 · Cited by 1,107
Gianni, A., Bregni, M., Stern, A., Siena, S., Tarella, C., Pileri, A., & Bonadonna, G. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90711-3 · Cited by 740
Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
Barlogie, B., Smith, L., & Alexanian, R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405243102104 · Cited by 641
Self-citationBarlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
Self-citationHIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Tricot, G. J. K., Jagannath, S., Vesole, D. H., Nelson, J., Tindle, S., Miller, L., Cheson, B. D., Crowley, J. J., & Barlogie, B. (1995) · Blood · doi:10.1182/blood.v85.2.588.588 · Cited by 452
Self-citationTricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S., & Sawyer, Jr. (1995) · Blood · doi:10.1182/blood.v86.11.4250.bloodjournal86114250 · Cited by 395
Self-citationCytogenetic findings in 200 patients with multiple myeloma
Sawyer, J. R., Waldron, J. A., Jagannath, S., & Barlogie, B. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)00284-i · Cited by 343
Self-citationHigh-dose melphalan with autologous bone marrow transplantation for multiple myeloma
Barlogie, B., Hall, R., Zander, A., Dicke, K., & Alexanian, R. (1986) · Blood · doi:10.1182/blood.v67.5.1298.1298 · Cited by 340
Self-citationC-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system
Bataille, R., Boccadoro, M., Klein, B., Durie, B., & Pileri, A. (1992) · Blood · doi:10.1182/blood.v80.3.733.733 · Cited by 294
Bartl, R., Frisch, B., Fateh-Moghadam, A., Kettner, G., Jaeger, K., & Sommerfeld, W. (1987) · American Journal of Clinical Pathology · doi:10.1093/ajcp/87.3.342 · Cited by 288
Barlogie, B., Alexanian, R., Dicke, K., Zagars, G., Spitzer, G., Jagannath, S., & Horwitz, L. (1987) · Blood · doi:10.1182/blood.v70.3.869.869 · Cited by 273
Self-citationMultiple myeloma: significance of plasmablastic subtype in morphological classification
Greipp, P., Raymond, N., Kyle, R., & O'Fallon, W. (1985) · Blood · doi:10.1182/blood.v65.2.305.305 · Cited by 263
Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor
Kwak, L. W., Duffey, P. L., Reynolds, C. W., Longo, D. L., Taub, D. D., Bensinger, W. I., & Bryant, E. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90757-2 · Cited by 256
Multiple myeloma treated with high dose intravenous melphalan
Selby, P. J., McElwain, T. J., Nandi, A. C., Perren, T. J., Powles, R. L., Tillyer, C. R., Osborne, R. J., Slevin, M. L., & Malpas, J. S. (1987) · British Journal of Haematology · doi:10.1111/j.1365-2141.1987.00045.x-i1 · Cited by 251
Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J., Viner, C., & Malpas, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.759 · Cited by 214
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Österborg, A., Yi, Q., Henriksson, L., Fagerberg, J., Bergenbrant, S., Jeddi-Tehrani, M., Rudén, U., Lefvert, A.-K., Holm, G., & Mellstedt, H. (1998) · Blood · doi:10.1182/blood.v91.7.2459 · Cited by 189
Vesole, D., Barlogie, B., Jagannath, S., Cheson, B., Tricot, G., Alexanian, R., & Crowley, J. (1994) · Blood · doi:10.1182/blood.v84.3.950.950 · Cited by 165
Self-citationHarousseau, J., Attal, M., Divine, M., Marit, G., Leblond, V, Stoppa, A., Bourhis, J., Caillot, D., Boasson, M., & Abgrall, J. (1995) · Blood · doi:10.1182/blood.v85.11.3077.bloodjournal85113077 · Cited by 159
Fermand, J., Lévy, Y., Gerota, J., Benbunan, M., Cosset, J. M., Castaigné, S., Seligmann, M., & Brouet, J. C. (1989) · Blood · doi:10.1182/blood.v73.1.20.20 · Cited by 151
Bensinger, W., Rowley, S. D., Demirer, T., Lilleby, K., Schiffman, K., Clift, R. A., Appelbaum, F. R., Fefer, A., Barnett, T., Storb, R. F., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1447 · Cited by 102
Powles, R., Raje, N. S., Milan, S., Millar, B. C., Shepherd, V., Mehta, M. P., Singhal, S., Kulkarni, S., Viner, C., Gore, M. E., et al. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700917 · Cited by 63
Self-citation
Cited by
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Metadata
- Authors
- Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B., & Crowley, J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-01-01
- Volume
- 93
- Issue
- 1
- Pages
- 55-65
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W181450122
- Cited by
- 472
- References
- 28
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.